businesspress24.com - Medivation Effects a 2-For-1 Forward Split of Its Common Stock
 

Medivation Effects a 2-For-1 Forward Split of Its Common Stock

ID: 1153567

(firmenpresse) - SAN FRANCISCO, CA -- (Marketwire) -- 09/24/12 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it has effected a 2-for-1 forward split of all shares of its common stock and increased the authorized number of shares of common stock.

The Company amended its certificate of incorporation on September 20 and 21, 2012 to increase the number of authorized shares of common stock from 50,000,000 to 170,000,000 and to effect a forward stock split pursuant to which each outstanding share of the Company's pre-split common stock was split into two shares of common stock, effective at 5:00 p.m. Eastern Time, on September 21, 2012. The shares of common stock issued pursuant to the forward stock split will be delivered to the Company's stockholders of record as of the record date, September 7, 2012, at their respective addresses of record appearing on the books of the Company. The Company's stockholders will not be required to surrender their existing certificates to receive the shares to be issued pursuant to the forward stock split. The number of shares of common stock issuable upon conversion of the Company's outstanding 2.625% Convertible Senior Notes due 2017 will be automatically adjusted to reflect the forward stock split. The Company's common stock will begin trading on a post-split basis on the NASDAQ Global Market at the opening of trading today, September 24, 2012.



Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at .



Patrick Machado
Chief Business & Financial Officer
(415) 829-4101

Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Clinical Ink Wins 2012 Data Driven Innovation Award From The Society of Clinical Data Management
Peregrine Pharmaceuticals Announces That It Has Discovered Major Discrepancies in Treatment Group Coding by an Independent Third-Party Vendor Responsible for Distribution of Blinded Investigational Product Used in Its Bavituximab Phase II Second-Line Non-
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 24.09.2012 - 05:00 Uhr
Sprache: Deutsch
News-ID 1153567
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

SAN FRANCISCO, CA


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 151 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Medivation Effects a 2-For-1 Forward Split of Its Common Stock
"
steht unter der journalistisch-redaktionellen Verantwortung von

Medivation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Medivation



 

Who is online

All members: 10 567
Register today: 2
Register yesterday: 0
Members online: 0
Guests online: 79


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.